Comparative Single-Dose mRNA and ChAdOx1 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2, Including Variants of Concern: Test-Negative Design, British Columbia, Canada

BACKGROUND: In British Columbia, Canada, most adults 50–69 years old became eligible for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in April 2021, with chimpanzee adenoviral vectored vaccine (ChAdOx1) restricted to ≥55-year-olds and second doses deferred ≥6 weeks to optimiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Skowronski, Danuta M, Setayeshgar, Solmaz, Zou, Macy, Prystajecky, Natalie, Tyson, John R, Sbihi, Hind, Fjell, Chris D, Galanis, Eleni, Naus, Monika, Patrick, David M, El Adam, Shiraz, Ahmed, May A, Kim, Shinhye, Henry, Bonnie, Hoang, Linda M N, Sadarangani, Manish, Jassem, Agatha N, Krajden, Mel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807316/
https://www.ncbi.nlm.nih.gov/pubmed/35084500
http://dx.doi.org/10.1093/infdis/jiac023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8807316/
https://www.ncbi.nlm.nih.gov/pubmed/35084500
http://dx.doi.org/10.1093/infdis/jiac023

Ejemplares similares